Micardis Expanded Prophylactic Indication Faces Safety Hurdle
This article was originally published in The Pink Sheet Daily
FDA’s cardio-renal advisory committee meets July 29 to assess comparative data to ramipril (the now generic Altace).
You may also be interested in...
CorVue would compete with Astellas’ Lexiscan in a market that has seen many product development failures recently.
Abbott/Boehringer Ingelheim's combined promotional force for Micardis will total 1,200 sales reps when joint promotional efforts begin in April.
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.